Evidence map›Paper›PMID 41964261›Full record

ArticleAnnals of clinical and translational neurology2026

Comprehensive Assessment of Arterial, Tissue, and Venous Collaterals for Evaluating the Infarct Growth Rate: The Multimodal Collateral Score.

Giorgio Busto, Umberto Pensato, Ilaria Casetta, Giorgio U Marcello, Angelo Barra, Anna Poggesi, Edoardo Carlesi, Sara Mancini, Andrea Ginestroni, Vittorio Miele and 3 more

Abstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giorgio BustoNeuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.ORCID https://orcid.org/0000-0002-7007-6030
Umberto PensatoDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Ilaria CasettaIRCCS San Camillo Hospital, Venice, Italy.
Giorgio U MarcelloNeuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.
Angelo BarraDepartment of Technical Health Professions and Rehabilitation, Careggi University Hospital, Florence, Italy.
Anna PoggesiStroke Unit, Careggi University Hospital, Florence, Italy.ORCID https://orcid.org/0000-0002-8694-0129
Edoardo CarlesiNeuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.
Sara ManciniNeuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.
Andrea GinestroniNeuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.
Vittorio MieleDepartment of Radiology, Careggi University Hospital, Florence, Italy.
Alessandro PadovaniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Andrea MorottiNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.ORCID https://orcid.org/0000-0002-6558-1155
Enrico FainardiNeuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.ORCID https://orcid.org/0000-0003-0477-724X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCollaterals are crucial factors that influence the infarct growth rate (IGR). We aimed to determine whether a comprehensive multimodal collateral score (MCS), incorporating collateral assessment at the arterial, tissue, and venous levels, is associated with functional independence and provides incremental prognostic value over individual IGR metrics.

methodsArterial collaterals were assessed using multiphase CT-angiography (mCTA), ranging from 0 to 5; tissue-level collaterals were evaluated on CT-perfusion by the hypoperfusion intensity ratio (HIR), ranging from 0 to 1; and venous outflow was measured on mCTA with the comprehensive venous outflow (CVO) score, ranging from 0 to 8. These metrics were used to develop the multimodal collateral score (MCS), which encompasses good mCTA collaterals (score 4-5), HIR (< 0.4), and CVO (range 4-8). The MCS ranges from 0 to 3, where 0 indicates no favorable collaterals, 1 means only one good collateral metric among the used ones, 2 signifies just two favorable collateral metrics differently combined among the used ones, and 3 represents the sum of all good collateral metrics. Multivariable logistic and ordinal regression analyses identified clinical and radiological factors independently associated with clinical outcomes (modified Rankin scale 0-2 at 90 days, ordinal mRS at 90 days).

resultsOverall, 615 acute ischemic stroke patients treated with thrombectomy within 24 h from symptom onset between January 2017 and December 2023 were included: the median age was 77 [IQR = 67-84], 320 (52%) were females, and 307 (50%) achieved functional independence. The MCS grades of 2 (aOR 2.92 [95% CI = 1.70-5.03]) and 3 (aOR 5.35 [95% CI = 3.03-9.44]) were independently associated with functional independence. The MCS was also independently associated with 90-day ordinal mRS (adjusted common odds ratio [acOR] 1.73 [95% CI = 1.51-2.01] per 1-point increase). The AUC of the MCS for predicting functional independence was 0.71 (95% CI = 0.66-0.75), which was superior to the other IGR metrics (p < 0.001).

conclusionMCS was a strong, independent predictor of favorable functional outcomes and demonstrated significantly superior prognostic performance compared with individual IGR metrics.

Indexed as

collateralscomprehensive venous outflowhypoperfusion intensity ratioinfarct growth ratemultiphase CT‐angiography

Identifiers

PMID41964261
PMCPMC13394072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.